Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Operating Leases: 2019-2024

Historic Operating Leases for Seres Therapeutics (MCRB) over the last 6 years, with Dec 2024 value amounting to $83.0 million.

  • Seres Therapeutics' Operating Leases fell 11.65% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year decrease of 11.65%. This contributed to the annual value of $83.0 million for FY2024, which is 9.48% down from last year.
  • Latest data reveals that Seres Therapeutics reported Operating Leases of $83.0 million as of FY2024, which was down 9.48% from $91.7 million recorded in FY2023.
  • Seres Therapeutics' 5-year Operating Leases high stood at $107.9 million for FY2022, and its period low was $10.6 million during FY2020.
  • Moreover, its 3-year median value for Operating Leases was $91.7 million (2023), whereas its average is $94.2 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 32.63% in 2020, then skyrocketed by 501.08% in 2022.
  • Over the past 5 years, Seres Therapeutics' Operating Leases (Yearly) stood at $10.6 million in 2020, then soared by 70.04% to $18.0 million in 2021, then soared by 501.08% to $107.9 million in 2022, then decreased by 15.09% to $91.7 million in 2023, then dropped by 9.48% to $83.0 million in 2024.